M&A

News

Investors take issue with Taisho Pharma’s buyout price

Two investment funds have decided to contest Taisho Pharma’s recently announced management buyout plan in court, after failing to reach an agreement on the price.

News

Ligand grows in cancer again with $100m Apeiron takeover

Ligand Pharmaceuticals has made its second major acquisition in 2024, agreeing a $100 million deal to buy Austria’s Apeiron Biologics and a royalty stream for brain cancer drug Qarziba.

News

Digital health financing shows signs of recovery in H1

After languishing in the doldrums for a few quarters, there are signs that the winds of investment are starting to blow again in the US digital health sector, according to market watcher Ro

News

Lilly swoops on Morphic to claim IBD drug candidate

Eli Lilly has bolstered its inflammatory bowel disease (IBD) pipeline with a $3.2 billion bid to acquire Morphic and its mid-stage oral integrin therapy MORF-057.

News

Grifols' executive chairman Thomas Glanzmann (l) and chief executive Nacho Abia (r)

Could Spain’s Grifols be heading for de-listing?

The family that owns Spanish drugmaker Grifols and private equity firm Brookfield are considering whether to take the company private in a deal that could be worth around €5.5 billion (almo

News

Radionetics Oncology's chief executive Paul Grayson

Lilly builds in radiopharma with $140m Radionetics deal

Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outr

Investors take issue with Taisho Pharma’s buyout price

Ligand grows in cancer again with $100m Apeiron takeover

Digital health financing shows signs of recovery in H1

Lilly swoops on Morphic to claim IBD drug candidate

Could Spain’s Grifols be heading for de-listing?

Lilly builds in radiopharma with $140m Radionetics deal

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

M&A

Editor's Picks